16 September 2021 in Proceedings of the National Academy of Sciences
Significance: Membrane proteins and their interactions are major drug targets because of their central roles in regulating cellular communication and signal transduction. Despite this, membrane receptors remain underrepresented in our knowledge base of protein–protein interactions because of the limitations of most available techniques. Here, we developed a vesicle-based membrane-protein display platform as a fast, reproducible, and broadly applicable method for unbiased receptor–ligand interaction discovery. Using this technology, we elucidated known and new single-pass transmembrane-binding partners for several immune checkpoint molecules as well as an architecturally distinct single-pass transmembrane protein that has resisted deorphanization by existing techniques. This method is well suited for extracellular protein interaction discovery for difficult-to-purify membrane proteins and whole vesicles.
8 December 2021 in PLOS ONE
The cancer-associated fibroblast (CAF) marker podoplanin (PDPN) is generally correlated with poor clinical outcomes in cancer patients and thus represents a promising therapeutic target. Despite its biomedical relevance, basic aspects of PDPN biology such as its cellular functions and cell surface ligands remain poorly uncharacterized, thus challenging drug development. Here, we utilize a high throughput platform to elucidate the PDPN cell surface interactome, and uncover the neutrophil protein CD177 as a new binding partner. Quantitative proteomics analysis of the CAF phosphoproteome reveals a role for PDPN in cell signaling, growth and actomyosin contractility, among other processes. Moreover, cellular assays demonstrate that CD177 is a functional antagonist, recapitulating the phenotype observed in PDPN-deficient CAFs. In sum, starting from the unbiased elucidation of the PDPN co-receptome, our work provides insights into PDPN functions and reveals the PDPN/CD177 axis as a possible modulator of fibroblast physiology in the tumor microenvironment.
5 August 2022 in Communications Biology
Receptor-ligand interactions on the plasma membrane regulate cellular communication and play a key role in viral infection. Despite representing main targets for drug development, the characterization of these interactions remains challenging in part due to the dearth of optimal technologies. Here, we build a comprehensive library of human proteins engineered for controlled cell surface expression. Coupled to tetramer-based screening for increased binding avidity, we develop a high throughput cell-based platform that enables systematic interrogation of receptor-ligand interactomes. Using this technology, we characterize the cell surface proteins targeted by the receptor binding domain (RBD) of the SARS-CoV spike protein. Host factors that specifically bind to SARS CoV-2 but not SARS CoV RBD are identified, including proteins that are expressed in the nervous system or olfactory epithelium. Remarkably, our results show that Contactin-1, a previously unknown SARS CoV-2 spike-specific receptor that is upregulated in COVID-19 patients, significantly enhances ACE2-dependent pseudotyped virus infection. Starting from a versatile platform to characterize cell surface interactomes, this study uncovers host factors specifically targeted by SARS CoV-2, information that may help design improved therapeutic strategies against COVID-19.
15 December 2019 in Annals of Oncology
Cell surface receptors fundamentally determine physiological and pathological signaling, and as such, deciphering the ensemble of receptor-ligand interactions in the extracellular milieu is vital to understand cellular communication and identify new therapeutic targets. Despite its clinical relevance, the Immunoglobulin Superfamily (IgSF) remains remarkably uncharacterized and many proteins, including some immune checkpoints, are orphan. In this study, we present the first experimentally validated map of receptor-ligand interactions, the IgSF Interactome. An automated platform for unbiased and high sensitivity receptor discovery was implemented. Using this technology, we interrogate 445 IgSF proteins for binding to most single transmembrane receptors in the human genome. The IgSF Interactome consists of over 500 interactions, with 85% previously unreported. Using orthogonal methodologies, we confirm loss-of-binding mutations specifically found in tumors, as well as new potential modulators for immune checkpoints such as PD-L1/PD-L2. Integration of this map of extracellular interactions with gene expression profiles in tumors and healthy tissues reveals receptor-ligand networks dysregulated in cancer. Furthermore, investigation of the IgSF Interactome in a large cohort of patients with metastatic urothelial cancer who were treated with the anti-PD-L1 agent Atezolizumab identifies interacting protein signatures associated with clinical outcome, suggesting new determinants of response to treatment. The IgSF Interactome represents the first map of receptor-ligand interactions in humans, providing a framework for understanding the functional organization of the surfaceome during homeostasis and disease, and ultimately informing therapeutic development. Genentech, Inc. Genentech, Inc. N. Martinez-Martin: Shareholder / Stockholder / Stock options: Roche. E. Verschueren: Shareholder / Stockholder / Stock options: Roche. B. Husain: Shareholder / Stockholder / Stock options: Roche.